The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends dapagliflozin for treating chronic kidney disease in line with NICE TA 775.

Dapagliflozin will be considered GREEN on the traffic light system.

Key considerations:
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.